Medicare Enrolled
Dr. Nagender Mankan, M.D.
Hematology & Oncology · Roswell, GA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mankan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mankan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mankan
Dr. Nagender Mankan is a hematology & oncology specialist in Roswell, GA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Mankan performed 811 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Mankan received a total of $12,264 from 68 pharmaceutical and/or device companies across 506 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mankan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 43% volume in GA
$12,264 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗811
Medicare services
Top 43% in GA for hematology & oncology
Not available
Unique patients (not deduplicated)
$74
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
438 | $72 | $280 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
125 | $47 | $199 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
51 | $95 | $253 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
47 | $62 | $178 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
41 | $102 | $341 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
38 | $99 | $384 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
38 | $140 | $442 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
19 | $27 | $123 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
14 | $91 | $382 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$12,264
Total received (2018-2024)
Avg $1,752/year across 7 years
Top 26% in GA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
68
Companies
506
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,713
2023
$3,537
2022
$2,046
2021
$908
2020
$754
2019
$2,831
2018
$476
Payments by company (2024)
Daiichi Sankyo Inc.
$225
PFIZER INC.
$220
AstraZeneca Pharmaceuticals LP
$212
Genentech USA, Inc.
$156
ABBVIE INC.
$131
Merck Sharp & Dohme LLC
$83
Gilead Sciences, Inc.
$73
E.R. Squibb & Sons, L.L.C.
$66
Stemline Therapeutics Inc.
$53
Eisai Inc.
$53
BeiGene USA, Inc.
$45
Regeneron Healthcare Solutions, Inc.
$34
Genmab U.S., Inc.
$30
GlaxoSmithKline, LLC.
$29
Acrotech Biopharma Inc.
$27
PharmaEssentia USA Corporation
$26
Fennec Pharmaceuticals, Inc.
$24
Mirati Therapeutics, Inc.
$24
JAZZ PHARMACEUTICALS INC.
$24
PUMA BIOTECHNOLOGY, INC.
$23
Takeda Pharmaceuticals U.S.A., Inc.
$22
Celgene Corporation
$21
Astellas Pharma US Inc
$21
Novartis Pharmaceuticals Corporation
$21
SOBI, INC
$20
Janssen Biotech, Inc.
$17
Alexion Pharmaceuticals, Inc.
$17
Karyopharm Therapeutics Inc.
$15
Top 3 companies account for 38.3% of 2024 payments
All-time payments by company (2018-2024) ›
CTI BioPharma Corp.
$1,761
Daiichi Sankyo Inc.
$869
AstraZeneca Pharmaceuticals LP
$858
Amgen Inc.
$710
Genentech USA, Inc.
$587
Celgene Corporation
$533
Novartis Pharmaceuticals Corporation
$513
Janssen Biotech, Inc.
$458
Merck Sharp & Dohme Corporation
$410
PFIZER INC.
$368
Astellas Pharma US Inc
$359
Incyte Corporation
$348
Seagen Inc.
$333
E.R. Squibb & Sons, L.L.C.
$296
Exelixis Inc.
$292
Merck Sharp & Dohme LLC
$250
Alexion Pharmaceuticals, Inc.
$204
ABBVIE INC.
$203
Regeneron Healthcare Solutions, Inc.
$202
Bayer HealthCare Pharmaceuticals Inc.
$201
Gilead Sciences, Inc.
$192
Boehringer Ingelheim Pharmaceuticals, Inc.
$138
GENZYME CORPORATION
$131
Karyopharm Therapeutics Inc.
$125
GlaxoSmithKline, LLC.
$117
Takeda Pharmaceuticals U.S.A., Inc.
$112
JAZZ PHARMACEUTICALS INC.
$111
Eisai Inc.
$110
Pharmacyclics LLC, An AbbVie Company
$100
Pharmacyclics LLC, an AbbVie Company
$99
Seattle Genetics, Inc.
$99
AMAG Pharmaceuticals, Inc.
$68
BeiGene USA, Inc.
$64
EISAI INC.
$64
Partner Therapeutics, Inc.
$63
Mirati Therapeutics, Inc.
$62
TerSera Therapeutics LLC
$60
Stemline Therapeutics Inc.
$53
TESARO, Inc.
$49
Rigel Pharmaceuticals, Inc.
$42
Lilly USA, LLC
$42
Epizyme, Inc.,
$36
AbbVie, Inc.
$33
Foundation Medicine, Inc.
$33
ARRAY BIOPHARMA INC
$31
Genmab U.S., Inc.
$30
Curium US LLC
$30
Heron Therapeutics, Inc.
$28
Acrotech Biopharma Inc.
$27
PharmaEssentia USA Corporation
$26
Fennec Pharmaceuticals, Inc.
$24
PUMA BIOTECHNOLOGY, INC.
$23
Clovis Oncology, Inc.
$22
Epizyme, Inc.
$22
SOBI, INC
$20
Bayer Healthcare Pharmaceuticals Inc.
$20
MACROGENICS, INC.
$19
Taiho Oncology, Inc.
$19
Coherus Biosciences Inc.
$18
SECURA BIO, INC.
$18
Sobi, Inc
$18
INSYS Therapeutics Inc
$18
Kite Pharma, Inc.
$17
Servier Pharmaceuticals LLC
$16
Advanced Accelerator Applications
$16
Organon LLC
$15
Kyowa Kirin, Inc.
$15
Puma Biotechnology, Inc.
$13
Top 3 companies account for 28.4% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALUNBRIG · AUGTYRO · Abraxane · Alecensa · Aliqopa · Avastin · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · CABOMETYX · CALQUENCE · CERDELGA · CINVANTI · COPIKTRA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Detectnet · ELAHERE · ELIQUIS · ELITEK · ELREXFIO · ENHERTU · EPKINLY · ERLEADA · Enhertu · Epkinly · Erleada · FARESTON · FASLODEX · FERAHEME · FOUNDATIONONE LIQUID CDX · FRUZAQLA · Fabhalta · GAUCHER-DISEASE · GAZYVA · GILOTRIF · Gazyva · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Inrebic · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · Leukine · Lonsurf · Lutathera · MARGENZA · MEKINIST · MONJUVI · MVASI · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Orserdu · PADCEV · PROMACTA · Padcev · Pedmark · Phesgo · Pomalyst · Prolia · REBLOZYL · RYBREVANT · RYZNEUTA · Revlimid · Rubraca · SANDOSTATIN · SUBSYS · Soliris · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tazverik · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · Venclexta · Vitrakvi · Vonjo · XALKORI · XGEVA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · ZEJULA · ZEPZELCA · ZOLADEX
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
166
County median income
$91,490
Nearest hospital to ZIP centroid (approximate)
WELLSTAR NORTH FULTON MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mankan is a clinical cardiology specialist, with moderate Medicare volume, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mankan experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Mankan performed 438 office visit, established patient (30-39 min) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Mankan receive payments from pharmaceutical companies?
Yes. Dr. Mankan received a total of $12,264 from 68 companies across 506 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mankan's costs compare to other hematology & oncology specialists in Roswell?
Dr. Mankan's average Medicare payment per service is $74. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mankan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Roswell
Browse hematology & oncology specialists in Roswell ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in GA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in GA
Which GA hematology & oncology specialists receive the most from drug and device companies.
By company
CTI BioPharma Corp. Payments to Doctors
See all physicians who received payments from CTI BioPharma Corp.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology